SUN-334 Evaluation of the CCK-2 Receptor Agonist (177)Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 "Lumed" Study

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). As MTC expresses cholecystokinine-2 (CCK-2) receptors at a high incidence and density, targeting the CCK-2 recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Rottenburger, Christof, Nicolas, Guillaume, McDougall, Lisa, Kaul, Felix, Cachovan, Michal, Schibli, Roger, Geistlich, Susanne, Behe, Martin, Wild, Damian, Christ, Emanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552824/
http://dx.doi.org/10.1210/js.2019-SUN-334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552824/
http://dx.doi.org/10.1210/js.2019-SUN-334

Ejemplares similares